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Introduction 
The pharmaceutical industry has a special place in the economy of any 
developed country. It is an important element in the health care system, thus 
ensuring the stability and sustainability of the development of human capital is 
an integral part of the industrial complex, its status largely characterizes the 
level of use of high technologies in the country. In Russia, the pharmaceutical 
industry is also an important part of the industrial complex (Strategical 
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ABSTRACT 
The urgency of the analyzed issue is due to the fact that the sustainable development of the economy 
of any country is the most important level of public health, which in turn, is conditioned by providing 
high quality pharmaceutical products. This is determined by the effective activity of the 
pharmaceutical industry, its competitiveness. Thus, the study of the competitiveness of Russian 
pharmaceutical enterprises, the development directions of its improvement should contribute to the 
sustainable development of the Russian economy. The article is focused on the development of 
organizational and economic ways of competitive recovery of the pharmaceutical industry. The 
leading approach to the study of this issue is an analytical approach that allows identifying the main 
directions of competitive recovery of the pharmaceutical industry. The results of the article: the 
study of possible organizational and economic ways of competitive recovery of Russian companies in 
the pharmaceutical industry, the algorithm of directions of its increase. The made recommendations 
have been tested in a number of Russian companies in the pharmaceutical industry. The article date 
may be useful in the management of the pharmaceutical industry now, as well as for understanding 
the specifics of the domestic pharmaceutical industry. 
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Development of the Russian Pharmaceutical Industry for the period up to 2020, 
2009). However, it has serious problems associated with the use of obsolete 
technologies, low-innovation component, and lack of breakthrough research and 
development of new drugs (Roy, 2011; Civaner 2012). All this reduces the 
competitiveness of the Russian pharmaceutical enterprises and requires the 
formation of a set of measures for its improvement.  
Special attention has always been paid to the problems associated with the 
competitive recovery of enterprises in the economic literature (Chesbrough, 
2010; Jasper, 2010; Shirokova, 2012). You can select a number of scientific 
schools, directions and recommendations both for the improvement of individual 
aspects of the competitiveness, and its level at every enterprise as a whole 
account (Angel, 2006). 
At the same time, the existing market conditions, the specifics of the 
Russian market and economic conditions, characteristics and problems of the 
development of the Russian pharmaceutical enterprises require new studies to 
ensure and enhance the competitiveness of the pharmaceutical industry. 
Materials and Methods 
Research methods 
In the course of research the following methods were used: theoretical (reviewed 
existing instruments of state influence on the development of the Russian 
pharmaceutical industry, the main tendencies of the dynamics of the 
pharmaceutical market, the prospects for strengthening the competitiveness of 
the Russian pharmaceutical companies.); diagnostic (algorithm choice of 
directions of its increase .The made recommendations have been tested in a 
number of Russian companies in the pharmaceutical industry.); empirical 
(distinguished and systematized features of the Russian pharmaceutical 
industry, affecting the competitiveness of enterprises in the market, economic, 
political and legal grounds); methods of mathematical statistics and graphic 
results. 
Experimental research base 
Experimental research base is pharmaceutical industrial enterprises of the 
Samara region. 
It is advisable to carry out the study of organizational and economic ways of 
competitive recovery of the Russian pharmaceutical industry in the following 
way: 
It is necessary to examine the current state, characteristics and problems of 
the development of the Russian pharmaceutical industry to identify the areas of 
their influence on the competitiveness of pharmaceutical enterprises (Report on 
the Activities of the Ministry of Industry and Trade of the Russian, 2015).  
It is advisable to clarify the concept of the competitiveness of the enterprise, 
taking into account the specificity of the pharmaceutical industry, since the 
characteristics of this concept in many ways determine the direction of further 
research. 
The development of a methodical approach to determine the 
competitiveness of pharmaceutical enterprises is an important element of this 
work. It will assess the achieved level in order to develop recovery ways. 
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The final stage of the study is to develop an algorithm which helps to choose 
the directions of competitive recovery of the pharmaceutical industry and to test 
the results. 
Results 
The status of the Russian pharmaceutical industry and pharmaceutical 
market at the recovery stage after its sharp decline 
Of course, the macro-economic conditions of recession affect its growth rate. 
However, in general, we could notice the positive dynamics of the development of 
pharmaceutical enterprises (Romanova, 2009; Lichtenberg, 2009). 
Taking into account these trends, as well as the importance of the 
pharmaceutical industry for the Russian economy as a whole, the government 
adopted a number of important measures for raising and strengthening of the 
Russian pharmaceutical industry, among which a special attention is paid to 
“Development Strategy of the Russian pharmaceutical industry for the period up 
to 2020” (Strategy PHARMA  2020) and the federal target program (FTP) 
“Development of the medical and pharmaceutical industry for the period up to 
2020 and beyond”. A distinctive feature of the Strategy is its complexity, because 
it takes into account the comments of such agencies as the Ministry of Defense, 
the Ministry of Economic Development, as well as the Federal Antimonopoly 
Service (FAS) of Russia. The final version of the PHARMA Strategy 2020 
includes proposals formed by the entities of Russia aimed at the development of 
pharmaceutical clusters. 
The increased attention to the pharmaceutical industry, the growth of the 
pharmaceutical market volumes as a whole corresponds to the global trend. 
Currently, the pharmaceutical industry is characterized by high growth rates 
both in the world and in Russia. The growth in the global market in average, 
according to various estimates, is from 6 to 10%, in the Russian market - from 4 
to 6% per year (see Table 1). 
 
Table 1. The basic indicators of the development of the pharmaceutical industry 
№ Indicator 2010 2012 2014 2015 2016  
value foreca
st 
1. The volume of the global 
pharmaceutical market 
(billion rubles) (in terms 
of rubles – 15 April, 
2015)  
44954 51108 59401 70642 76380 
2. The volume of the 
Russian pharmaceutical 
market (billion rubles)  
735 919 1174 1291 1415 
3. The production dynamics 
of pharmaceutical 
substances in Russia 
(thousands of imputed 
tons)  
1522,7 1338,7 1177 1102 1050 
Source: It is made by authors 
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However, the growth of the domestic pharmaceutical market is due to lower 
production volumes of its own pharmaceutical substances and active 
pharmaceutical ingredients (API), and is due, above all, to increased production 
of medicines (drugs) and other types of pharmaceutical products by foreign 
companies. 
The basis of the domestic production of drugs is foreign substances and the 
API. The volume of Russian production of pharmaceutical substances has 
decreased since the beginning of 1990 by 5.5 times. This study has allowed 
determining a fairly positive outlook for the Russian pharmaceutical market. 
Features and development problems of the Russian pharmaceutical 
industry 
The conducted analysis shows that the emerging trends of the pharmaceutical 
market growth is largely based on the import substances growth from 
industrialized countries and it does not allow solving a number of very 
important issues for the development of the domestic pharmaceutical industry. 
The author's classification of problems of the domestic pharmaceutical industry. 
The most important of the above problems is the lag of the Russian 
pharmaceutical industry in the production of foreign substances according to 
their value, production volume and quality. The impact of the cost factor has 
also increased significantly due to changes in the national currency. Among the 
very important problems you may also mention technological backwardness of 
the Russian enterprises, the low level of investment in research and 
development, and a high level of wear and tear of the equipment. This 
significantly reduces the competitiveness of enterprises of the Russian 
pharmaceutical industry. 
The pharmaceutical industry has specific features that influence the 
activities of manufacturers. Author's classification of these features is shown in 
Figure 1. 
 
Characteristics  
 Market Economic Politico-legal 
F
e
a
tu
re
s 
Market saturation by foreign 
pharmaceutical enterprises  
High innovation 
potential of foreign 
manufacturers  
Active intervention by 
government 
Orientation of Russian 
manufacturers on generic drugs 
production 
Long development and 
production process 
Complex process of new 
drugs and active 
pharmaceutical 
ingredients entry (APIs) 
Research and capital intensity 
of pharmaceutical production  
 
Dependence of 
domestic 
pharmaceutical 
industry on imported 
raw materials  
Clustering policy of the 
pharmaceutical industry  
Figure 1.  Classification of the features of the pharmaceutical industry  
Source: The table is drawn up on the basis of the data of the analytical agency DSM Group 
(www.dsm.ru) and IMS Health, 2014  
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In describing these features, it can be noted that not all of them are now 
taken into account in the development directions of the Russian pharmaceutical 
industry, especially in terms of innovation potential, high-tech products. We 
need elaborate further actions for the state support of this industry, for example, 
to accelerate the process of drugs registration, and to reduce the cost of 
production on the basis of industrial clustering policy. 
It is especially important in assessing the achieved level of the 
competitiveness of enterprises, choosing the organizational and environmental 
measures for its improvement, developing recommendations for the government. 
Accounting of these features would further permit the development directions to 
improve the competitiveness (COM) of pharmaceutical industrial enterprises. 
Clarifying the concept of the competitiveness of the enterprise in 
order to get its better compliance with the specifics of the 
pharmaceutical industry 
The competitiveness of enterprises is closely linked to the competitiveness of the 
economy as a whole and also its individual sectors and industries. The effective 
demand of the population, the development of innovative technologies 
(combinatorial chemical technologies, screening materials, biotechnology, etc.), 
pharmacy chains, legislative and legal restrictions affect the competitiveness of 
pharmaceutical enterprises. 
The existing approaches to the interpretation of the concept “the 
competitiveness of the enterprise” little emphasize the importance of the 
relationship of internal, external, current and prospective businesse 
opportunities with various levels of the COM of the economy. The importance of 
the relationship is, first of all, in the influence of the COM of the economy on 
specific features of the enterprise. The features of enterprises form competitive 
advantages, the implementation of which enhances their competitiveness in 
certain economic conditions. 
As a result of the analysis of various authors’ interpretations, the authors of 
this work clarify the concept of the competitiveness of the enterprise as a 
combination of its external and internal, current and future opportunities - 
industrial, economic, technical and technological, human resources, innovation, 
interrelated with the economic competitiveness at micro-, meso- and macro- 
levels ensuring the formation of competitive advantage for their use in 
competition taking into account the conditions of doing business. 
Development of the methodical approach to determine the 
competitiveness of pharmaceutical enterprises 
Based on the study of different approaches to the evaluation of the 
competitiveness of the enterprise the authors form their methodical approach to 
its evaluation, taking into account the specificity of the pharmaceutical industry. 
It involves two stages: at the first - they prepare and conduct an expert 
estimation: the analysis of statistical reporting, financial and non-financial 
aspects of the organization, the expert survey. 
The second stage involves the quantitative and qualitative methods to analyze 
the competitiveness. It, in its turn, involves the evaluation of the values of 
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particular indicators of the competitiveness and the construction of its 
integrated indicator. 
The proposed list of specific indicators of the COM of the enterprise (in 
groups) is presented in Table 2. 
 
Table 2. The list of specific indicators of the competitiveness of the enterprise (for groups). 
“Internal factors” (specific volume and 
performance indicators of the enterprise): 
“External factors” (indicators of 
the enterprise activity in the 
market): 
1) revenue from sales  
2) profitability (sales, production, assets) 
3) share of exported products 
4) revenues from sales of blockbuster drugs 
5) number of commodity headings 
6) coefficients of financial stability and autonomy 
7) number of produced orphan drugs 
8) number of patented drugs 
9) working capital turnover 
10) ratio of sales volume to the amount of 
receivables 
1) number of pharmaceutical 
distributors 
2) market share of the enterprise 
3) order book 
4) effectiveness of advertising 
(expert review) 
 
 “Current Status” (recourse indicators):  “Perspectives” (performance 
development trends of the 
enterprise and market): 
 
1) value of fixed assets 
2) average number of employees 
3) capacity utilization 
4) cost of research 
 
 
1) ratio of strategic positioning 
2) projected sales volume 
(production) 
3) ratio of the product index 
4) ratio of innovation activity 
5) ratio of market development 
Source: It is made by authors 
 
For the construction of the integral index of the competitiveness of the 
pharmaceutical enterprise it is advisable to use an algorithm that consists of the 
following steps. 
     1. Initial data array of primary data for a particular indicator Yi are 
normalized by dividing their greatest value Ymax. As a result we calculate the 
coefficients (Ki), reflecting the ratio of every indicator value to the maximum, 
equal to a 1:  
                                                            
max
i
Y
Y
K i  
Thus, the interval of possible values is in the range from 0 (worst value) and 1 
(best). For ease of interpretation the index could be transformed into a 
percentage (0 ... 100%). 
The deduction of the selected indicators to a normalized, comparable form is 
carried out taking into account that not all particular indicators have the same 
interpretation of values (for example, the decline of values may indicate an 
improvement). 
Calculation of the average value of indicators for each unit: 
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
, where 
iK

 - the average value of the unit i, 
in -  the number of the indexes of the unit i. 
Calculation of the integrated coefficient (J), adjusted for the appropriate 
weighting coefficient obtained by expertise: 
                              
100
....21 iniiiii GKGKGK
J



,where 
iК

 - the average value of the unit i, 
iG - the weighting coefficient of the unit i. 
4. The interpretation of the received appraisal of J: the worst value - 0%; the 
closer it is to 100%, the higher the COM of the enterprise is. 
Testing of the proposed recommendations 
The proposed recommendations will be considered using the example of a 
number of pharmaceutical enterprises of the Samara region of the Russian 
Federation: LLC “Pranafarm”, LLC “STK Farm”, LLC “Ozone”. These companies 
are generally typical enterprises of the Russian pharmaceutical industry with an 
average production volume. The basis of their production is generic products; 
LLC “STK Farm” produces the same single-use syringes, medical films and 
consumables. In the production process is involved equipment by such 
manufacturers as FETTE, KILLIAN, NOACK, FREWITT, STREA and others. 
The total indicators of the competitiveness of the analyzed pharmaceutical 
enterprises are presented in the table 3. 
 
Table 3. Index summary of the competitiveness of  pharmaceutical enterprises in 2012-2014 
Year Enterprise 
LLC “Pranafarm” LLC “STK-
PHARM” 
LLC “Ozon”  
2012 0,581 0,679 0,680 
2013 0,590 0,693 0,691 
2014 0,623 0,718 0,717 
2015 0,671 0,723 0,721 
Source: The table is drawn up on the basis of calculations according to the proposed 
method, 2015. 
In 2015 the leader among the considered enterprises was “STK-PHARM”. 
The value of its integrated evaluation can be the following: the level of the 
competitiveness of the enterprise is 72.3% of the “ideal”, the highest possible 
level in 2015. The worst result (67.1%) had LLC “Pranafarm”. 
On the basis of the proposed algorithm, which helps to choose the directions, the 
authors formulate recommendations to improve the COM of LLC “Pranafarm”. 
It has been found that to improve the COM of the enterprise it is necessary to 
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implement an investment project aimed at increasing production and product 
base. The calculations show that the project is effective. According to estimates, 
the net present value (NPV) amounts to 558.9 million rubles, the internal rate of 
return (IRR) - 28%. More details are given in the table 4. 
 
Table 4. Indicators of industrial activity of LLC "Pranafarm" as a result of the investment 
program 
№ Years 
Indicator 2016 2017 2018 
1 Production volumes: total (mln. 
packages) 
180  210  300  
2 Including the list of vital essential 
drugs (VED) (mln. packages) 
100  120  180  
3 Product quantity  (items) 75 80 90 
4 Number of innovation commodity 
headings (items) 
0 0 4 
5 Market share (%) 0,0030 0,0033 0,004 
6 Amount of profit (thousand rubles) 402 000 528 900 611 800 
Source: The table is drawn up on the basis of calculations according to the proposed 
method, 2015. 
 
The dynamics of indicators of the COM of the pharmaceutical company LLC 
“Pranafarm” for 2017-2019 years, calculated according to the proposed method, 
providing the implementation of the proposed recommendations are presented in 
the table 5. 
 
Table 5. Indicators of industrial activity of LLC "Pranafarm" as a result of the investment 
program 
2017  2018  2019  
0,640 0,677 0,680 
Source: The table is drawn up on the basis of calculations according to the proposed 
method, 2015 
 
The integral indicator of the competitiveness of the enterprise has a stable 
upward trend, and its value indicates that by 2019 its competitiveness will be 
68% of the “perfect”, the maximum possible. 
Discussions 
The article represents the organizational and economic directions of competitive 
recovery of pharmaceutical industrial enterprises. The authors specify the 
notion of the competitiveness of the enterprise taking into account the 
peculiarities of the pharmaceutical industry, suggest the methodical approach to 
determine its competitiveness, and develop the algorithm for choosing the 
directions of its recovery. The subject of the discussion can be: the author's 
interpretation of the concept of the competitiveness, the stages of the methodical 
approach to its definition, their sequence, a set of indicators selected for 
evaluation. The method of calculating the integral index of the competitiveness 
and the proposed algorithm to choose the directions of competitive recovery of 
pharmaceutical enterprises can be the subjects of discussion. 
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The proposed organizational and economic directions of competitive 
recovery of industrial enterprises of the pharmaceutical industry can be used by 
manufacturers at any stage of its development. The identified evidence suggests 
a two-valued situation that takes place right now and on the one hand it 
expresses an increase in the global pharmaceutical market volumes, and on the 
other hand it shows a parallel reducing the competitiveness of some Russian 
producers. In this situation the tools of competitive recovery of enterprises, as 
well as the estimating methods can be considered highly relevant. 
Currently there are some scientific works to improve the situation in the 
Russian pharmaceutical industrial enterprises. The individual elements of these 
works can be compared with the results of other authors, in particular in the 
methodical approach of determining the competitiveness, the stage approach to 
its definition, as well as a set of indicators for its evaluation. However, the 
proposed work has the features that differentiate it from the works that have 
been previously proposed by the authors. 
The value of these results is the relative simplicity of the proposed 
implementation management tools to improve the competitiveness of 
pharmaceutical enterprises, and it avoids the need to involve specialized experts 
and to have recourse to more complex economic tools. 
Theoretical and practical developments in the field of raising the 
competitiveness of industries represented in the works of A. Nemtsev (2007), 
S.N. Sirazhitdinova & B.J. Tatarskih (2012), G.I. Yakovlev (2013). The issues of 
the competitiveness of pharmaceutical enterprises are considered in the 
scientific works of E.A. Tretyakova (2012), A.V. Evstratov (2003) and others. 
It is worth noting that in the above studies, the issues of the development of 
organizational-economic directions to improve the competitiveness of the 
pharmaceutical enterprises have not been examined yet. 
Conclusion 
The proposed organizational and economic ways of competitive recovery of the 
Russian enterprises in the pharmaceutical industry will enable the solution of 
important problems in their economic activities, and strengthen their position in 
the market. Using a methodical approach to determining the competitiveness of 
the enterprise will allow more reasonably evaluating its achieved level, the 
developed algorithm to choose the directions of its improvement - to generate 
recommendations in order to improve the competitiveness of the enterprise 
taking into account the special features of the pharmaceutical industry. In 
general, the practical implementation of these proposals will enhance the 
stability of the Russian pharmaceutical enterprises, and will increase the 
efficiency of their business. 
Recommendations  
The data of the article may be useful in the management of the pharmaceutical 
industry now, as well as for understanding the specifics of the domestic 
pharmaceutical industry. 
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